• Lonnie Granier

ONDCP: Elimination of X-Waiver Requirement Announced Prematurely

Office of National Drug Control Policy: "On January 14, 2021, HHS announced forthcoming Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder. Unfortunately, the announcement was made prematurely. Therefore, the Guidelines previously announced cannot be issued at this time. However, HHS and ONDCP are committed to working with interagency partners to examine ways to increase access to buprenorphine, reduce overdose rates and save lives."

10 views0 comments

Recent Posts

See All

FDA Approves Higher Dosage of Naloxone

The Food and Drug Administration recently announced the approval of a higher dose of naloxone nasal spray to treat opioid overdose. The FDA previously approved 2 mg and 4 mg naloxone products and has